Loading…
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-169M | $-161M | $-139M | -35.2% | - | - |
| 2024 | - | - | - | - | - | - | - |
| 2023 | - | - | - | - | - | - | - |
| 2022 | - | - | - | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | - | - | - | 0 |
| Operating Revenue | - | - | - | 0 |
| Operating Expense | - | - | - | 169.08 |
| Research And Development | - | - | - | 138.35 |
| Selling General And Administration | - | - | - | 30.73 |
| Total Expenses | - | - | - | 169.08 |
| Operating Income | - | - | - | -169.08 |
| Total Operating Income As Reported | - | - | - | -169.08 |
| EBITDA | - | - | - | -168.50 |
| Normalized EBITDA | - | -56.73 | - | -168.50 |
| EBIT | - | - | - | -169.08 |
| Interest Income | - | - | - | 5.52 |
| Net Interest Income | - | - | - | 5.52 |
| Other Non Operating Income Expenses | - | -0.51 | - | 2.41 |
| Other Income Expense | - | - | - | 2.41 |
| Interest Income Non Operating | - | - | - | 5.52 |
| Net Non Operating Interest Income Expense | - | - | - | 5.52 |
| Pretax Income | - | - | - | -161.15 |
| Tax Rate For Calcs | - | - | - | 0 |
| Tax Effect Of Unusual Items | - | - | - | 0 |
| Net Income Continuous Operations | - | - | - | -161.15 |
| Net Income From Continuing And Discontinued Operation | - | - | - | -161.15 |
| Net Income From Continuing Operation Net Minority Interest | - | - | - | -161.15 |
| Net Income | - | - | - | -161.15 |
| Net Income Common Stockholders | - | - | - | -161.15 |
| Net Income Including Noncontrolling Interests | - | - | - | -161.15 |
| Normalized Income | - | -55.71 | - | -161.15 |
| Diluted NI Availto Com Stockholders | - | - | - | -161.15 |
| Basic Average Shares | - | - | 26.18 | 8.68 |
| Diluted Average Shares | - | - | 26.18 | 8.68 |
| Reconciled Depreciation | - | - | - | 0.58 |
| General And Administrative Expense | - | - | - | 30.73 |
| Other Gand A | - | - | - | 9.05 |
| Salaries And Wages | - | - | - | 21.69 |
| Earnings From Equity Interest | - | - | - | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| MapLight Therapeutics, Inc.this co. | MPLT | $1.4B | - | 2.98 | -35.2% | - |
| AtriCure, Inc. | ATRC | $1.4B | -120.63 | 2.81 | -2.3% | 79.22 |
| Precigen, Inc. | PGEN | $1.4B | -5.49 | 65.81 | -1198.6% | -5.93 |
| Integra LifeSciences Holdings Corporation | IART | $1.4B | -2.65 | 1.31 | -49.5% | -9.72 |
| Butterfly Network, Inc. | BFLY | $1.4B |
| - |
| 6.93 |
| -39.3% |
| - |
| UroGen Pharma Ltd. | URGN | $1.3B | -8.76 | -12.75 | 145.5% | -10.04 |
| Bicara Therapeutics Inc. | BCAX | $1.3B | -9.72 | 3.34 | -34.4% | -8.01 |
| Inhibrx Biosciences, Inc. | INBX | $1.3B | -9.56 | 167.49 | -1752.2% | -10.54 |
| Ardelyx, Inc. | ARDX | $1.3B | -21.66 | 7.99 | -36.9% | -50.52 |
| Peer Median | - | -9.56 | 5.13 | -38.1% | -9.72 | |